کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4934914 | 1434058 | 2017 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia
ترجمه فارسی عنوان
یک کارآزمایی کنترل شده به صورت تصادفی 12 هفته ای در دوزخ روزانه اکسیتوسین اینترنال در نقص شناختی اجتماعی افراد مبتلا به اسکیزوفرنیا
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
PANSSGSSSspAmITT - MITTVSs - VSSSchizoaffective disorder - اختلال SchizoaffectiveSchizophrenia - اسکیزوفرنی یا شیزوفرنیmodified intention-to-treat - اصلاح قصد درمانoxytocin - اکسیتوسینReading the Mind in the Eyes Test - خواندن ذهن در آزمون چشمPsychosis - روان پریشیSocial cognition - شناخت اجتماعیnegative symptoms - علائم منفیpositive and negative syndrome scale - مقیاس مثبت و منفی سندرمinternational units - واحدهای بین المللی
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
علوم اعصاب رفتاری
چکیده انگلیسی
Social cognition is impaired in people with schizophrenia and these deficits are strongly correlated with social functioning. Oxytocin is a hypothalamic peptide that contributes to maternal infant bonding and has diverse pro-social effects in adults. This study tested the hypothesis that 12Â weeks of intranasal oxytocin will improve social cognitive function in outpatients with schizophrenia and schizoaffective disorder. Sixty-eight eligible participants were randomized to oxytocin (24Â IU twice daily) or placebo. Social cognitive function was assessed using the Emotion Recognition-40, Brüne Theory of Mind, Reading the Mind in the Eyes test, Trustworthiness task and Ambiguous Intentions Hostility Questionnaire at baseline, 6Â weeks and 12Â weeks. In addition, social function was assessed using the Specific Levels of Functioning Scale and a role-play test, and psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Fifty-five participants completed the 12-week trial. The study found no evidence for a differential advantage of oxytocin over placebo on social cognition. Among secondary outcomes, there was a modest advantage for oxytocin over placebo on a component of social functioning, although there was also evidence that the placebo group outperformed the oxytocin group on the role-play task. No between-group differences emerged on measures of psychopathology in pre-specified comparisons, but oxytocin showed significant within-group reduction in PANSS negative symptoms and significant between-group improvement in negative symptoms in the schizophrenia subgroup. Further testing is needed to clarify whether oxytocin has therapeutic potential for social cognitive deficits and/or negative symptoms in people with schizophrenia.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Schizophrenia Research - Volume 185, July 2017, Pages 88-95
Journal: Schizophrenia Research - Volume 185, July 2017, Pages 88-95
نویسندگان
L. Fredrik Jarskog, Cort A. Pedersen, Jacqueline L. Johnson, Robert M. Hamer, Shane W. Rau, Tonya Elliott, David L. Penn,